SANUWAVE Health, Inc. (SNWV)
| Market Cap | 158.56M |
| Revenue (ttm) | 44.05M |
| Net Income (ttm) | 11.81M |
| Shares Out | 8.59M |
| EPS (ttm) | 0.41 |
| PE Ratio | 45.22 |
| Forward PE | 47.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 152,606 |
| Open | 18.50 |
| Previous Close | 18.46 |
| Day's Range | 18.35 - 19.33 |
| 52-Week Range | 16.27 - 46.59 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 51.00 (+176.42%) |
| Earnings Date | May 11, 2026 |
About SNWV
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and ch... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SNWV stock is "Strong Buy." The 12-month stock price target is $51.0, which is an increase of 176.42% from the latest price.
News
SANUWAVE Health Earnings Call Transcript: Q4 2025
Record Q4 and full-year revenue growth driven by UltraMIST system sales and consumables, despite industry disruption from CMS reimbursement changes. Strategic channel shift to resellers and strong cash position support 2026 growth outlook of 16%–25%.
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Q4 2025 revenues were $13.4 million , up 29.7% from Q4 2024. This was an all-time quarterly record for the Company.
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
EDEN PRAIRIE, Minn., March 20, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will...
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Health Reports Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply
Healogics Wound Care Supply adds UltraMIST to its Group Purchasing Organization Healogics iSupply and Sanuwave collaborate to provide UltraMIST as an option for GPO members EDEN PRAIRIE, Minn., Dec. 0...
SANUWAVE Health Earnings Call Transcript: Q3 2025
Q3 2025 set new revenue and unit sales records, with 22% year-over-year growth and strong gross margins. Net income swung to $10.3 million, aided by non-cash gains and a patent sale. Guidance for Q4 anticipates continued record growth as reimbursement uncertainty eases.
Sanuwave Announces Q3 FY2025 Financial Results
Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will ...
Aehr Test Systems Posts Q1 Earnings, Joins SANUWAVE Health And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history.
Sanuwave Announces Strategic Debt Refinancing with New Credit Facility
Credit facility from J.P. Morgan consists of a four-year term loan of $23 million and a two-year $5 million revolving credit facility backed by accounts receivable Both the term loan and revolver have...
SANUWAVE Health Transcript: AGM 2025
The virtual meeting covered director elections, auditor ratification, equity plan amendment, and executive compensation votes. A quorum was present, voting was completed online, and results will be disclosed in a Form 8-K. No stockholder questions were submitted.
SANUWAVE Health Earnings Call Transcript: Q2 2025
Q2 2025 revenue rose 42% year-over-year to $10.2M, with gross margin up to 78.3% and strong UltraMIST adoption. Guidance for Q3 is $12M–$12.7M, with new applicator design expected to further boost margins in 2026. Senior debt refinancing and expanded sales force support continued growth.
Sanuwave Announces Q2 FY2025 Financial Results
Q2 2025 revenues were $10.2 million , up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results
EDEN PRAIRIE, Minn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will ...
Sanuwave Health to Present at Canaccord Genuity Growth Conference
EDEN PRAIRIE, Minn., July 22, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, FDA-approved wound care products , today announced, that Morgan Fran...
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is ple...
Sanuwave Health Selected for Inclusion in Russell 2000® Index
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NASDAQ: SNWV), a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 20...
Sanuwave Health Appoints Greg Bazar to Board of Directors
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (Nasdaq:SNWV), a leading provider of next-generation FDA-approved wound care products, is plea...
SANUWAVE Health Earnings Call Transcript: Q1 2025
Q1 2025 saw 61% revenue growth, record system placements, and improved gross margins, exceeding guidance. Net loss increased due to non-cash expenses, but adjusted EBITDA turned positive. Guidance for Q2 and full-year 2025 remains strong.
Sanuwave Announces Q1 FY2025 Financial Results
Q1 2025 revenues were $9.3 million , up 61% from $5.8 million in Q1 2024. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results
EDEN PRAIRIE, Minn., May 05, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history.
SANUWAVE Health Earnings Call Transcript: Q4 2024
Record Q4 and full-year revenue achieved with strong growth in system placements and consumables. Gross margin expanded to 77.9%, and adjusted EBITDA improved significantly. Guidance for 2025 targets 50% revenue growth, with a strengthened balance sheet and expanded salesforce.
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results
Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company.